Therapeutic agents

Abstract

(“CDK2”) activation (e.g., CCNE1 dependent CDK2 activation) and / or CDK2 complex formation and / or CDK2 complex activity. Non-limiting examples of said complexes include CDK2 / cyclin complexes, e.g., CDK2 / cyclin E1 complex (also referred to herein as CDK2 / CCNE1). The chemical entities are useful, e.g., for treating a condition, disease or disorder in which (i) increased (e.g., excessive) CDK2 activation (e.g., CCNE1 dependent CDK2 activation), (ii) CDK2 complex formation and / or (iii) CDK2 complex activity contribute to the pathology and / or symptoms and / or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.